Loading, Please Wait...
DOYLESTOWN, Pa., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today reported net sales of $1.7 million for the three months ended June 30, 2019 compared to net sales of $3.2 million for the three months ended June 30, 2018.
The Company incurred a net loss for the three months ended June 30, 2019, of $1.2 million, or ($0.11) per share, compared to a net loss of $260,000, or ($0.02) per share, for the three months ended June 30, 2018.
Results for the second quarter of 2019 compared to the second quarter of 2018 principally reflect the net effect of (i) a decrease in net sales of $1.5 million due to a decrease in shipments and (ii) an increase in sales and marketing costs of $107,000, offset by a decrease in administrative costs of $108,000 due principally to a decrease in legal and professional costs.
The Company generated net sales for the six months ended June 30, 2019 of $4.0 million, a decrease of $2.6 million, or 39.4%, as compared to $6.6 million for the six months ended June 30, 2018.
The Company incurred a net loss for the six months ended June 30, 2019 of $2.3 million, or ($0.19) per share, compared to a net loss of $216,000, or ($0.02) per share, for the six months ended June 30, 2018.
Results for the six months ended June 30, 2019 compared to the six months ended June 30, 2018 principally reflect the net effect of (i) a decrease in net sales of $2.6 million and (ii) an increase in sales and marketing costs of $201,000, offset by a decrease in administrative costs of $123,000 due principally to a decrease in legal and professional costs.
Mr. Karkus stated, “Over the past year, we succeeded in hiring new, talented senior management for Pharmaloz Manufacturing, our wholly owned manufacturing facility. Pharmaloz is in the process of purchasing additional equipment to expand our production capacity and capabilities. We believe there is a continuing trend for retailers to seek to grow their private label businesses at the expense of branded products. Our forward planning includes making sure we are and remain well-positioned to grow our private label manufacturing business with retailers.”
Mr. Karkus also noted, “During the quarter ended June 30, 2019, our ProPhase Digital Media subsidiary completed the optimization phase for digital distribution of our lead product, Legendz XL®. However, the resultant sales have been below levels we are satisfied with to date. We are therefore in the process of restructuring this division, decreasing overhead and potentially partnering this division with other companies. At the same time, we are in the process of seeking to develop an e-commerce platform with experienced retailers.”
Mr. Karkus added, “In addition to digital distribution, we continue to ship our new dietary supplement, Legendz XL®, to a major retail drug chain and other retailers. We recently received orders from an additional major retail drug chain as well as a large supermarket chain. We are also starting to penetrate the convenience store channel. We are pleased with the progress we have made to date in achieving a critical mass of retailers for our lead dietary supplement, Legendz XL®. However, the successful implementation of our dietary supplement strategy will require significant investment in marketing as well as significant additional distribution within the various retail channels and e-commerce venues in order to achieve a successful launch and build a successful new product line. This follows the model we successfully executed for our prior Cold-EEZE® brand.”
Mr. Karkus concluded, “The Company continues to explore a wide range of acquisition opportunities in the consumer products space, as well as investments and acquisitions in other sectors and industries.”
About the Company
We are a vertically integrated and diversified branding, marketing and technology company with deep experience with over-the-counter (“OTC”) consumer healthcare products, dietary supplements and other remedies. We are engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products, dietary supplements and other remedies in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand, a wholly-owned subsidiary of the Company.
In addition, the Company also continues to actively pursue acquisition opportunities for other companies, technologies and products inside and outside the consumer products industry. For more information visit us at www.ProPhaseLabs.com.
Forward Looking Statements
Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our plans to expand our production capacity and capabilities at Pharmaloz, our plans with respect to ProPhase Digital Media, the implementation of our dietary supplement strategy, and potential acquisition opportunities. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to: the difficulty of predicting the acceptance and demand for our products, the impact of competitive products and pricing, costs involved in the manufacture and marketing of products, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.
Ted Karkus, Chairman and CEO
ProPhase Labs, Inc.
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
|For the Three Months Ended||For the Six Months Ended|
|June 30, 2019||June 30, 2018||June 30, 2019||June 30, 2018|
|Cost of sales||1,390||1,928||3,188||3,910|
|Sales and marketing||342||235||608||407|
|Research and development||95||87||189||174|
|Total operating expenses||1,529||1,522||3,093||3,000|
|Loss from operations||(1,268||)||(264||)||(2,312||)||(316||)|
|Interest income, net||30||4||61||100|
|Other comprehensive income:|
|Unrealized gain on marketable debt securities||8||68||23||25|
|Total comprehensive loss||$||(1,230||)||$||(192||)||$||(2,228||)||$||(191||)|
|Basic loss per share||$||(0.11||)||$||(0.02||)||$||(0.19||)||$||(0.02||)|
|Diluted loss per share||$||(0.11||)||$||(0.02||)||$||(0.19||)||$||(0.02||)|
|Weighted average common shares outstanding:|
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
|June 30, 2019||December 31, 2018|
|Cash and cash equivalents||$||1,049||$||1,554|
|Marketable debt securities, available for sale||$||4,685||$||6,687|
|Accounts receivable, net||$||738||$||2,968|
|Total current assets||$||13,429||$||18,238|
|Total current liabilities||$||956||$||4,233|
|Total non-current liabilities||$||191||$||-|
|Total stockholders' equity||$||14,652||$||16,504|